AIM ImmunoTech Stock Forward View - Triple Exponential Smoothing
| AIM Stock | USD 0.68 -0.02 -2.86% |
Forecasting AIM ImmunoTech stock price is inherently uncertain, but structured approaches to analyzing market sentiment can improve the odds. This module tracks the noise around AIM ImmunoTech to identify periods where price and perception diverge.
Based on the latest data, the 14-period RSI for AIM ImmunoTech stands at 37, indicating moderately negative momentum. This range suggests moderated price movement without extreme directional pressure.Momentum
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter -0.98 | EPS Estimate Current Year -7.74 | EPS Estimate Next Year -4.33 | Wall Street Target Price 13.986 | Quarterly Revenue Growth -0.26 |
The hype perspective for AIM ImmunoTech maps headline activity to recent price response and peer coverage.
AIM RSI Reading
The Triple Exponential Smoothing forecasted value of AIM ImmunoTech on the next trading day is expected to be 0.66 with a mean absolute deviation of 0.06 and the sum of the absolute errors of 3.67.Headline Hype vs Price - AIM ImmunoTech
Behavioral finance research confirms that investor sentiment drives AIM ImmunoTech's price in the short term. By quantifying that sentiment from news and social signals, investors can better time entries and exits in AIM.
AIM ImmunoTech's investor sentiment is not always right, but it is always relevant. Understanding the current mood of the market toward AIM ImmunoTech helps investors assess whether current prices reflect greed, fear, or rational expectation.
The Triple Exponential Smoothing forecasted value of AIM ImmunoTech on the next trading day is expected to be 0.66 with a mean absolute deviation of 0.06 and the sum of the absolute errors of 3.67.AIM ImmunoTech after-hype prediction price | $ 0.63 |
Sentiment metrics here complement forecasting and technical views with analyst and earnings context.
Historical Fundamental Analysis of AIM ImmunoTech can be used to cross-verify projections for AIM ImmunoTech. The view provides historical context for the projection set.AIM ImmunoTech Additional Predictive Modules
Most predictive techniques to examine AIM price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for AIM using various technical indicators. When you analyze AIM charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
AIM ImmunoTech Triple Exponential Smoothing Price Forecast For the 13th of March 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of AIM ImmunoTech on the next trading day is expected to be 0.66 with a mean absolute deviation of 0.06 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 3.67 .Please note that although there have been many attempts to predict AIM Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that AIM ImmunoTech's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
AIM ImmunoTech Stock Forecast Pattern
| Backtest AIM ImmunoTech | AIM ImmunoTech Price Prediction | Research Analysis |
AIM ImmunoTech Forecasted Value
This next-day forecast for AIM ImmunoTech uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of AIM ImmunoTech stock data series using in forecasting. Note that when a statistical model is used to represent AIM ImmunoTech stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0128 |
| MAD | Mean absolute deviation | 0.0623 |
| MAPE | Mean absolute percentage error | 0.0565 |
| SAE | Sum of the absolute errors | 3.6747 |
The mean reversion principle applied to AIM ImmunoTech's suggests that neither prolonged outperformance nor underperformance is permanent. Investors exploit this by positioning against extremes in price relative to fundamental value.
AIM ImmunoTech After-Hype Price Density Analysis
Probability distributions applied to AIM ImmunoTech price forecasting provide a more honest representation of uncertainty than single point estimates. The shape of AIM ImmunoTech's distribution - whether it is symmetric, skewed, or fat-tailed - carries important information for risk.
Next price density |
| Expected price to next headline |
AIM ImmunoTech Estimiated After-Hype Price Volatility
News-driven price analysis for AIM ImmunoTech quantifies the historical relationship between headline events and AIM ImmunoTech's short-term price response. AIM ImmunoTech's after-hype downside and upside margins for the prediction period are 0.03 and 10.33, respectively. The strength of this signal depends on the consistency of AIM ImmunoTech's past reactions to comparable news categories.
Current Value
The after-hype framework applied to AIM ImmunoTech assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
AIM ImmunoTech Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as AIM ImmunoTech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AIM ImmunoTech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with AIM ImmunoTech, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.76 | 9.70 | 0.05 | 0.01 | 10 Events | 6 Events | In 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.68 | 0.63 | 6.71 |
|
AIM ImmunoTech Hype Timeline
On the 12th of March 2026 AIM ImmunoTech is traded for 0.68. The company has historical hype elasticity of -0.05, and average elasticity to hype of competition of 0.01. AIM is forecasted to decline in value after the next headline, with the price expected to drop to 0.63. The average volatility of media hype impact on the company price is over 100%. The price depreciation on the next news is expected to be -6.71%, whereas the daily expected return is presently at -0.76%. The volatility of related hype on AIM ImmunoTech is about 121250.0%, with the expected price after the next announcement by competition of 0.69. The company has Price/Earnings To Growth (PEG) ratio of 0.71. AIM ImmunoTech recorded a loss per share of 18.16. The company last dividend was issued on the 11th of June 2019. The firm completed a 1031:1000 stock split on 10th of February 2026. Considering the 90-day investment horizon the next forecasted press release will be in 10 days. Historical Fundamental Analysis of AIM ImmunoTech can be used to cross-verify projections for AIM ImmunoTech. The view provides historical context for the projection set.AIM ImmunoTech Related Hype Analysis
When a direct competitor of AIM ImmunoTech experiences a significant news event, the market often re-rates AIM ImmunoTech's shares in sympathy or in contrast, depending on whether the news affects the sector broadly or competitively.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| KALA | Kala Pharmaceuticals | 0.03 | 5 per month | 0.00 | -0.16 | 12.28 | -10.77 | 33.89 | |
| OGEN | Oragenics | -0.03 | 7 per month | 5.11 | 0.04 | 11.36 | -8.33 | 24.70 | |
| KTTA | Pasithea Therapeutics Corp | 0.01 | 7 per month | 0.00 | -0.09 | 4.82 | -7.75 | 22.36 | |
| VYNE | Vyne Therapeutics | 0.01 | 5 per month | 1.89 | 0.14 | 3.57 | -5.00 | 55.08 | |
| QNRX | Quoin Pharmaceuticals Ltd | 0.11 | 10 per month | 0.00 | -0.10 | 10.80 | -9.33 | 42.02 | |
| ENSC | Ensysce Biosciences | -0.06 | 7 per month | 0.00 | -0.13 | 11.27 | -14.08 | 70.00 | |
| XTLB | XTL Biopharmaceuticals Ltd | 0.03 | 8 per month | 0.00 | -0.01 | 8.25 | -11.21 | 69.70 | |
| TCRT | Alaunos Therapeutics | -0.07 | 7 per month | 5.11 | 0.02 | 9.61 | -8.26 | 24.31 | |
| CANF | Can Fite Biopharma | 0.08 | 7 per month | 0.00 | -0.06 | 10.00 | -10.33 | 43.99 | |
| SNGX | Soligenix | -0.03 | 9 per month | 0.00 | -0.05 | 5.22 | -6.25 | 24.24 |
Other Forecasting Options for AIM ImmunoTech
Regardless of investment experience, understanding AIM ImmunoTech's price movement is essential for anyone considering a position in AIM. Price charts for AIM Stock are often filled with noise that can lead to poor investment choices if not properly filtered.AIM ImmunoTech Related Equities
The following equities are related to AIM ImmunoTech within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing AIM ImmunoTech against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
AIM ImmunoTech Market Strength Events
Market strength indicators for AIM ImmunoTech give investors insight into the stock's responsiveness to broader market forces. Tracking these indicators helps investors make informed timing decisions and identify periods where trading AIM ImmunoTech is likely to be most rewarding.
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.68 | |||
| Day Typical Price | 0.68 | |||
| Price Action Indicator | -0.01 | |||
| Period Momentum Indicator | -0.02 | |||
| Relative Strength Index | 37.71 |
AIM ImmunoTech Risk Indicators
A thorough review of AIM ImmunoTech's risk indicators is an important first step in forecasting its price and managing investment exposure. This analysis helps investors determine the appropriate level of risk to accept when holding AIM ImmunoTech's.
| Mean Deviation | 5.51 | |||
| Standard Deviation | 9.46 | |||
| Variance | 89.56 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for AIM ImmunoTech
Coverage intensity for AIM ImmunoTech matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
AIM ImmunoTech Short Properties
Short sentiment tied to AIM ImmunoTech matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 1.5 M | |
| Cash And Short Term Investments | 4 M |
More Resources for AIM Stock Analysis
Understanding AIM ImmunoTech typically begins with financial statements and long-term trend review. Ratio context helps frame profitability, efficiency, and growth trends for AIM ImmunoTech Stock. Outlined below are key reports that provide context for AIM ImmunoTech Stock:Historical Fundamental Analysis of AIM ImmunoTech can be used to cross-verify projections for AIM ImmunoTech. The view provides historical context for the projection set. New to investing in AIM Stock? Start with our How to Invest in AIM Stock guide for a step-by-step overview.Analysis related to AIM ImmunoTech should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Earnings Share -18.16 | Revenue Per Share | Quarterly Revenue Growth -0.26 | Return On Assets | Return On Equity |
AIM ImmunoTech market price can diverge from book value, the accounting figure shown on AIM balance sheet. AIM ImmunoTech's market capitalization is 2.85 M. A P/B ratio of 2.72 indicates the market values AIM ImmunoTech above its accounting book value. Enterprise value stands at 2.78 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish AIM ImmunoTech's value from its trading price, which are computed with different methods. For AIM ImmunoTech, key inputs include a P/E ratio of 12.5, a P/B ratio of 2.72, ROE of -31.39%, and revenue of 170 K. The quoted price is simply the exchange level where supply meets demand.